ArticleFrontiers in medicine2026
Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a highly promising treatment for advanced hepatocellular carcinoma, hepatic arterial infusion chemotherapy with raltitrexed plus oxaliplatin is gaining increasing clinical acceptance. However, in patients with colorectal cancer, treatment with oxaliplatin is associated with severe adverse reactions, such as hemolytic anemia and acute kidney injury. The potential occurrence of such adverse reactions in patients with hepatocellular carcinoma and the corresponding management strategies should be investigated. In this report, we present a case of severe hemolytic anemia and acute kidney injury in a patient with hepatocellular carcinoma after hepatic arterial infusion chemotherapy with raltitrexed plus oxaliplatin therapy, which was suspected to be oxaliplatin-related. The patient achieved complete clinical resolution through two personalized sessions of exchange transfusion, supplemented with artificial liver support therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.